IL276623A - Dosing regimens of B7-H4 antibody - Google Patents
Dosing regimens of B7-H4 antibodyInfo
- Publication number
- IL276623A IL276623A IL276623A IL27662320A IL276623A IL 276623 A IL276623 A IL 276623A IL 276623 A IL276623 A IL 276623A IL 27662320 A IL27662320 A IL 27662320A IL 276623 A IL276623 A IL 276623A
- Authority
- IL
- Israel
- Prior art keywords
- dosing regimens
- antibody dosing
- antibody
- regimens
- dosing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633527P | 2018-02-21 | 2018-02-21 | |
| US201962802100P | 2019-02-06 | 2019-02-06 | |
| PCT/US2019/018963 WO2019165075A1 (en) | 2018-02-21 | 2019-02-21 | B7-h4 antibody dosing regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL276623A true IL276623A (en) | 2020-09-30 |
Family
ID=65686103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276623A IL276623A (en) | 2018-02-21 | 2020-08-10 | Dosing regimens of B7-H4 antibody |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20210070862A1 (https=) |
| EP (1) | EP3755719A1 (https=) |
| JP (2) | JP7258038B6 (https=) |
| KR (1) | KR102863169B1 (https=) |
| CN (1) | CN111868089B (https=) |
| AU (1) | AU2019226009B2 (https=) |
| BR (1) | BR112020016990A2 (https=) |
| CA (1) | CA3091161A1 (https=) |
| IL (1) | IL276623A (https=) |
| MA (1) | MA51902A (https=) |
| MX (1) | MX2020008730A (https=) |
| SG (1) | SG11202007820QA (https=) |
| WO (1) | WO2019165075A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3672990A1 (en) | 2017-08-25 | 2020-07-01 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| JP2021514379A (ja) * | 2018-02-21 | 2021-06-10 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｂ７−ｈ４抗体製剤 |
| MA52416A (fr) | 2018-03-02 | 2021-04-21 | Five Prime Therapeutics Inc | Anticorps b7-h4 et leurs procédés d'utilisation |
| WO2020081497A1 (en) * | 2018-10-15 | 2020-04-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| JP2024501894A (ja) | 2021-01-04 | 2024-01-16 | メルサナ セラピューティクス インコーポレイテッド | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| CA2478297C (en) | 2002-03-19 | 2013-05-14 | Plant Research International B.V. | Optimizing glycan processing in plants |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| CN103540600B (zh) | 2003-01-22 | 2017-12-01 | 罗氏格黎卡特股份公司 | 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途 |
| JP2008539753A (ja) | 2005-05-09 | 2008-11-20 | グリクアート バイオテクノロジー アクチェンゲゼルシャフト | 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子 |
| BRPI0707290A2 (pt) | 2006-01-17 | 2011-08-16 | Biolex Therapeutics Inc | composições e métodos para humanização e otimização de n-glicanas em plantas |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| JP6120848B2 (ja) * | 2011-08-15 | 2017-04-26 | メディミューン，エルエルシー | 抗ｂ７−ｈ４抗体およびその使用 |
| AU2013361275B2 (en) * | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| PH12021552742A1 (en) | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| CN107299085B (zh) * | 2017-05-26 | 2020-09-29 | 广东医科大学 | 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用 |
| EP3672990A1 (en) * | 2017-08-25 | 2020-07-01 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| JP2021514379A (ja) * | 2018-02-21 | 2021-06-10 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｂ７−ｈ４抗体製剤 |
-
2019
- 2019-02-21 EP EP19709318.0A patent/EP3755719A1/en active Pending
- 2019-02-21 WO PCT/US2019/018963 patent/WO2019165075A1/en not_active Ceased
- 2019-02-21 KR KR1020207026649A patent/KR102863169B1/ko active Active
- 2019-02-21 CA CA3091161A patent/CA3091161A1/en active Pending
- 2019-02-21 SG SG11202007820QA patent/SG11202007820QA/en unknown
- 2019-02-21 MA MA051902A patent/MA51902A/fr unknown
- 2019-02-21 BR BR112020016990-0A patent/BR112020016990A2/pt not_active Application Discontinuation
- 2019-02-21 CN CN201980019155.0A patent/CN111868089B/zh active Active
- 2019-02-21 JP JP2020544277A patent/JP7258038B6/ja active Active
- 2019-02-21 MX MX2020008730A patent/MX2020008730A/es unknown
- 2019-02-21 AU AU2019226009A patent/AU2019226009B2/en active Active
-
2020
- 2020-08-10 IL IL276623A patent/IL276623A/en unknown
- 2020-08-19 US US16/997,581 patent/US20210070862A1/en not_active Abandoned
-
2022
- 2022-09-27 US US17/935,805 patent/US20230287123A1/en not_active Abandoned
-
2023
- 2023-04-04 JP JP2023060944A patent/JP2023089063A/ja active Pending
-
2024
- 2024-06-12 US US18/741,328 patent/US20240317864A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111868089A (zh) | 2020-10-30 |
| JP2023089063A (ja) | 2023-06-27 |
| MA51902A (fr) | 2021-05-26 |
| AU2019226009B2 (en) | 2025-11-20 |
| AU2019226009A1 (en) | 2020-09-03 |
| SG11202007820QA (en) | 2020-09-29 |
| WO2019165075A1 (en) | 2019-08-29 |
| US20210070862A1 (en) | 2021-03-11 |
| EP3755719A1 (en) | 2020-12-30 |
| JP7258038B2 (ja) | 2023-04-14 |
| MX2020008730A (es) | 2020-12-07 |
| US20230287123A1 (en) | 2023-09-14 |
| KR20200123169A (ko) | 2020-10-28 |
| JP7258038B6 (ja) | 2023-04-25 |
| US20240317864A1 (en) | 2024-09-26 |
| BR112020016990A2 (pt) | 2021-02-23 |
| KR102863169B1 (ko) | 2025-09-22 |
| CN111868089B (zh) | 2025-08-22 |
| CA3091161A1 (en) | 2019-08-29 |
| JP2021513997A (ja) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279321A (en) | Anti-SIRPalpha antibody | |
| IL280780A (en) | Anti-TIGIT antibodies | |
| IL283812A (en) | Humanized antibody against human pd–1 | |
| IL280013A (en) | Anti-IL36R antibodies | |
| IL278061A (en) | Structures of antibodies against ROR | |
| IL279352A (en) | IL-11RA antibodies | |
| IL278010A (en) | Antibodies to galectin 10 | |
| GB201817172D0 (en) | Antibody | |
| IL276623A (en) | Dosing regimens of B7-H4 antibody | |
| IL282756A (en) | Humanized antibodies against SIRPα | |
| IL276626A (en) | Formulations of B7-H4 antibody | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| IL277030A (en) | Antibodies | |
| ZA202101177B (en) | Anti-btla antibody | |
| GB201811368D0 (en) | Antibody | |
| SG11202102114UA (en) | Anti-klrg1 antibodies | |
| GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| GB201806084D0 (en) | Antibodies | |
| IL280515A (en) | Dosing regimens for elagolix | |
| GB201910138D0 (en) | Anti-pd-l1 antibodies | |
| HK40041710A (en) | B7-h4 antibody dosing regimens | |
| EP3703728A4 (en) | DOSING SCHEMES FOR COELIAKIA | |
| GB201511196D0 (en) | Monoclonal antibodies | |
| HK40054775A (en) | Dosing regimens for elagolix |